We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 22.36 | 3.04% | 757.33 | 757.7899 | 736.00 | 738.04 | 1,486,097 | 17:55:13 |
From May 2019 to May 2024
By Dave Sebastian
Eli Lilly & Co. (LLY) said it has struck an agreement with DexCom Inc. (DXCM) to use Dexcom products in Lilly's currently developed personalized diabetes management system.
Under the non-exclusive agreement, Lilly said Monday it would use Dexcom's continuous glucose monitoring devices in both the pen- and pump-based platforms of the system.
The pen-based platform aims to integrate personalized data from a prefiled, disposable insulin pen with data from glucose-sensing technologies into a compatible software application, Lilly said.
Lilly said the pump-based platform is a hybrid-closed-loop system that would automate insulin dosing by integrating an insulin pump, continuous glucose monitor and a handheld controller or smartphone application that controls the system.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
December 16, 2019 07:12 ET (12:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
